Tadalafil Lilly ICOS

Current Opinion in Investigational Drugs

Volumn 4, Issue 1, 2003, Pages 60-65

  Rotella, David P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ERYTHROMYCIN; GG 960; ICOS 351; KETOCONAZOLE; LY 450190; NITRATE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

AREA UNDER THE CURVE; BACKACHE; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERTENSION; IC 50; LICENSING; NONHUMAN; NOSE CONGESTION; PATENT; PENIS ERECTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CARBOLINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 0037286720     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. 216701 Sildefanil (Viagra™), a potent and selective inhibitor of type 5 CGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Terrett NK, Bell AS, Brown D, Ellis P Bioorg Med Chem Lett 1996 6 15 1819-1824
2. 240438 Drug development digest: ICOS Corp. Emerging Pharmaceuticals 1997 6 4 13
3. 319481 Lilly and Chugai enter into a new collaboration to speed the development of Lilly compounds in Japan. Eli Lilly & Co Press Release 1999 March 25
4. 409025 Chugai starts V's 21 plan: President Nagayama. Pharma Jpn 2001 1745 1
5. 413921 Lilly ICOS LLC submits NDA for Cialis for treatment of ED. Lilly ICOS LLC Press Release 2001 June 28
6. 416200 Oral drug therapy for erectile dysfunction. Padma-Nathan H, Giuliano F Urol Clin North Am 2001 28 2 321-334
7. 420746 FDA accepts Cialis NDA. ICOS Corporation Press Release 2001 August 31
8. 434250 Lilly reports on status of FDA manufacturing reinspection. Eli Lilly & Co Press Release 2001 December 19
9. 434420 Eli Lilly, Chugai to dissolve their JV. Pharm J 2001 1775
10. 436220 Eli Lilly & Co. Hambrecht & Quist 2002 January 7-10 134
11. 449103 ICOS reports results for first quarter of 2002. ICOS Corporation Press Release 2002 April 23
12. 449855 Lilly ICOS LLC receives approvable letter from FDA for Cialis for the treatment of erectile dysfunction. Lilly ICOS LLC Press Release 2002 April 30
13. 455368 ICOS Corp. Int Biotech Conv & Exhib 2002 Suppl June 9-12
14. 459219 Cialis receives positive opinion from European Committee for proprietary medicinal products. Lilly ICOS LLC Press Release 2002 July 25
15. 466274 Tadalafil for the treatment of erectile dysfunction receives positive recommendation from the Australian Drug Evaluation Committee. Eli Lilly & Co Press Release 2002 September 03
16. 470201 Cialis - Tadalafil - Approved by European Commission for the treatment of erectile dysfunction. Lilly ICOS LLC Press Release 2002 November 14
17. 470256 Drug development pipeline: ICAM-5 modulator, ICAM-4, casein kinase 1 inhibitors, ICAM-3 antibodies, CCR5 antagonists, IC747, α-D, resiniferatoxin, Pafase, tadalafil. ICOS Corporation Company Communication 2002 470256
18. 474170 Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Haning H, Niewohner U, Schenke T, Es-Sayed M, Schmidt G, Lampe T, Bischoff E Bioorg Med Chem Lett 2002 12 6 865-868
19. 474172 Tadalafil (Cialis) for men with erectile dysfunction. Eardley I, Cartledge J Int J Clin Pract 2002 56 4 300-304 This paper gives a useful and current overview of tadalfil.
20. 474175 Pharmacology of phosphodiesterase-5 inhibitors. Corbin JD, Francis SH Int J Clin Pract 2002 56 6 453-459
21. 474248 IC351 (tadalafil, Cialis): Update on clinical experience. Porst H Int J Impot Res 2002 14 1 S57-S64 This paper summarizes many of the clinical trials of tadalafil.
22. 474250 Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S J Urol 2002 168 4 Pt 1 1332-1336 This paper presents an excellent analysis of the late stage trials of tadalafil.
23. 474268 Effects of tadalafil on erectile dysfunction in men with diabetes. Saenz De Tejada I, Anglin G, Knight JR, Emmick JT Diabetes Care 2002 25 12 2159-2164
24. 474275 Vardenafil a potent and selective inhibitor of phosphodiesterase type 5 increases cGMP in rabbit corpus cavernosum. Bischoff E, Niewoehner U, Haning H, Es Sayed M, Scenke T, Schlemmer KH Int J Impot Res 2000 12 3 S65.2
25. 474278 Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension. Padma-Nathan H, Brock G, McMahon C, Chen KK, Anglin G, Costigan T, Shen W, Watkins V, Whitaker JS Am J Hypertens 2002 15 A143
26. 474280 Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension. Hutter AM, Kloner RA, Watkins V, Costigan T, Bedding A, Mitchell M, Emmick J Am J Hypertens 2002 15 A140
27. 474283 Tadalafil: An oral selective phosphodiesterase 5 inhibitor for treatment of erectile dysfunction. Kim SS, Narayanan S, Song JC Formulary 2002 37 289-296
28. 474284 Dose-normalized pharmacokinetics of tadalafil (IC351) administered as a single dose to healthy volunteers. Patterson B, Bedding A, Jewell H et al Congress European Society Sexual Impotence Research 2001
29. 474286 The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Patterson B, Bedding A, Jewell H et al Congress European Society Sexual Impotence Research 2001
30. 474288 The effect of IC351 taken as needed for treatment of erectile dysfunction in men with diabetes. De Saenz TI, Emmick J, Anglin G et al Congress European Society Sexual Impotence Research 2001
31. 474298 Viagra (sildenafil citrate). Physician's Desk Reference 2002
32. 474559 Effects of IC351 on erectile response to visual sexual stimulation. Meuleman E, Nycklama N, Slob K, Roeleveid L, Damen L, Brazao G, Padma-Nathan H, Raymond R J Urol 1999 161 212 Abs 814
33. 474658 CIALIS™ (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED). Padma-Nathan H, Rosen RC, Shabsigh R, Saikali K, Watkins VS, Pullman B J Urol 2001 165 Suppl 5 923
34. 474671 Efficacy and safety of IC351 treatment for ED. Brock G, Iglesias J, Toulouse K, Ferguson K, Pullman W, Anglin G Eur Urol 39 Suppl 5 224 Abs 923
35. 475623 The investors' guide to therapeutics and drug pipelines. Credit Suisse First Boston Ltd 2002 November 15 103 In November 2002, Credit Suisse Fist Boston Ltd predicted an estimated domestic peak sales potential of US $1 billion for Cialis.
36. 475871 Clinical safety profile of sildenafil in Singaporean men with erectile dysfunction: Pre-marketing experience (ASSESS-I evaluation). Lim PH, Ng FC, Cheng CW, Wong MY, Chee CT, Moorthy P J Int Med Res 2002 30 2 137-143
37. 475892 US Major Pharmaceuticals: New product approval analysis Risinger D, Boris J, Li B, Calone J Merrill Lynch & Co 2003 January 02
38. 475906 Chugai Lilly Clinical Research: End of joint venture. Eli Lilly & Co Company Communication 2003 January 10